CorMatrix® Cardiovascular, Inc. receives FDA IDE approval to conduct the safety and feasibility clinical trial of the Cor™ TRICUSPID ECM® valve for pediatric and adult patients

CorMatrix® Cardiovascular, Inc. www.cormatrix.com, a leading developer of regenerative cardiovascular medical devices, today announced FDA approval of an early feasibility study IDE to evaluate the safety and feasibility of the Cor™ TRICUSPID ECM® cardiac valve for...
SEARCH FOR STUDIES